This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Mast-Cell Stabilizing Effects of Olopatadine

This study has been completed.
Information provided by:
Alcon Research Identifier:
First received: October 13, 2006
Last updated: November 18, 2016
Last verified: January 2010
To assess the effects of olopatadine of the release of mast cell histamine

Condition Intervention Phase
Allergic Conjunctivitis Drug: Olopatadine (generic name) Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Mast-Cell Stabilizing Effects of Olopatadine

Resource links provided by NLM:

Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Tear histamine

Secondary Outcome Measures:
  • Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness

Enrollment: 24
Study Start Date: October 2006
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Asymptomatic and not using any topical or systemic medication

Exclusion Criteria:

  • Age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00389025

Padova Site
Padova, Italy
Sponsors and Collaborators
Alcon Research
Study Director: Terry Wiernas Alcon Research
  More Information

Additional Information: Identifier: NCT00389025     History of Changes
Other Study ID Numbers: C-05-30
Study First Received: October 13, 2006
Last Updated: November 18, 2016

Keywords provided by Alcon Research:
Subject with clinical history of seasonal allergic conjunctivitis

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Olopatadine Hydrochloride
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on July 19, 2017